About Apelin receptor
Apelin receptor (APLNR) is a protein
from Homo sapiens identified by UniProt accession
P35414, 380 residues long.
MolForge cross-references it against 0 known binders and
306 disease associations.
Target properties
| Protein name | Apelin receptor |
|---|
| UniProt accession | P35414 |
|---|
| Gene | APLNR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (306)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.27
- breast adenocarcinoma · score 0.17
- head and neck squamous cell carcinoma · score 0.16
- high density lipoprotein cholesterol measurement · score 0.15
- neoplasm · score 0.11
- platelet-to-lymphocyte ratio · score 0.10
- monocyte percentage of leukocytes · score 0.09
- insulin resistance · score 0.08
- pulmonary arterial hypertension · score 0.07
- coronary artery disease · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P35414-F1 | alphafold | PREDICTED | 81.71 | — |
Amino-acid sequence (380 residues)
MEEGGDFDNY YGADNQSECE YTDWKSSGAL IPAIYMLVFL LGTTGNGLVL WTVFRSSREK RRSADIFIAS LAVADLTFVV TLPLWATYTY RDYDWPFGTF FCKLSSYLIF VNMYASVFCL TGLSFDRYLA IVRPVANARL RLRVSGAVAT AVLWVLAALL AMPVMVLRTT GDLENTTKVQ CYMDYSMVAT VSSEWAWEVG LGVSSTTVGF VVPFTIMLTC YFFIAQTIAG HFRKERIEGL RKRRRLLSII VVLVVTFALC WMPYHLVKTL YMLGSLLHWP CDFDLFLMNI FPYCTCISYV NSCLNPFLYA FFDPRFRQAC TSMLCCGQSR CAGTSHSSSG EKSASYSSGH SQGPGPNMGK GGEQMHEKSI PYSQETLVVD
Explore Apelin receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets